Use lowest tolerable hydrocortisone dose in central adrenal insufficiency
STEP 1 — Gather Information
Confirm central AI diagnosis, document current hydrocortisone dose and schedule, assess for symptoms of over- or under-replacement (weight gain, hypertension, hyperglycemia, fatigue, hypotension), and review cardiovascular/metabolic risk factors (BMI, BP, lipids, glucose). Proceed to evaluate dose tolerance.
STEP 2 — Rule In / Rule Out
Is central adrenal insufficiency confirmed and requiring glucocorticoid replacement? If yes, continue to Step 3; if no, this skill does not apply.
STEP 3 — Classify or Stratify
Assess whether the current dose exceeds the lowest tolerable level by checking for glucocorticoid over-replacement signs (central obesity, striae, elevated fasting glucose, hypertension, dyslipidemia) versus under-replacement signs (persistent fatigue, orthostatic hypotension, hypoglycemia). If over-replacement signs are present, consider dose reduction; if under-replacement signs are present, maintain or increase dose; if equivocal, proceed to a cautious taper.
STEP 4 — Decide
Titrate hydrocortisone downward in small increments (e.g., 2.5–5 mg reductions) while monitoring for adequacy of replacement (absence of AI symptoms, stable weight, normal glucose/BPs) and adverse effects, aiming for the lowest dose that prevents adrenal insufficiency symptoms and maintains well-being.
Clinical Guardrails / Mimics / Pitfalls
Avoid abrupt discontinuation that risks adrenal crisis; ensure patient has stress-dose education and emergency kit; do not reduce dose below physiological needs if symptoms of insufficiency appear; monitor for Cushingoid features with over-replacement; individualize based on comorbidities and clinical context.
Concrete Clinical Example
A 50‑year‑old woman with central AI on HC 20 mg daily reports mild weight gain and borderline hypertension; morning cortisol is adequate. Dose is reduced to 15 mg daily (10 mg AM, 5 mg PM). After 3 months, weight stabilizes, BP improves, and she remains free of adrenal insufficiency symptoms.
Source: Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2016, DOI:10.1210/jc.2016-2118